This page shows the latest Odefsey news and features for those working in and with pharma, biotech and healthcare.
Gilead gets EU nod for TAF-based triple therapy for HIV. Once-daily, single-tablet Odefsey reduces risks of side effects such as renal and bone toxicity. ... Gilead Sciences has added to its portfolio of HIV drugs in Europe after getting EMA approval for
Descovy was approved by the US FDA earlier this month, while a three-drug combination called Odefsey (emtricitabine, rilpivirine and TAF) - a follow-up to its $1.4bn Complera product - was
Descovy is the third TAF-based HIV drug in Gilead's portfolio - joining its other once-daily treatments Genvoya and Odefsey - and adds to the biopharmaceutical firm's dominance in the
Gilead wins US approval for second TAF-based HIV drug. FDA gives Odefsey the green light. ... Gilead Sciences has added another new product to its HIV franchise following FDA approval of Odefsey, a three-drug regimen taken as a single small tablet once a
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
No results were found
MAT offers an information exchange called Rapid Payer Response that allows healthcare stakeholders to secure immediate, global, expert insight and...